Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Medtronic
Moodys
Harvard Business School
Merck
Colorcon
Boehringer Ingelheim

Last Updated: July 2, 2020

DrugPatentWatch Database Preview

Neos Theraps Inc Company Profile


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the competitive landscape for NEOS THERAPS INC, and what generic alternatives to NEOS THERAPS INC drugs are available?

NEOS THERAPS INC has two approved drugs.

There are six US patents protecting NEOS THERAPS INC drugs.

There are two patent family members on NEOS THERAPS INC drugs in two countries.

Summary for Neos Theraps Inc
International Patents:2
US Patents:6
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Neos Theraps Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-001 Jun 19, 2017 RX Yes No 9,089,496   Start Trial Y   Start Trial
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-002 Jun 19, 2017 RX Yes No 8,840,924   Start Trial Y   Start Trial
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-001 Jun 19, 2017 RX Yes No 9,072,680   Start Trial Y   Start Trial
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-003 Jun 19, 2017 RX Yes No 9,089,496   Start Trial Y   Start Trial
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-003 Jun 19, 2017 RX Yes No 9,072,680   Start Trial Y   Start Trial
Neos Theraps Inc COTEMPLA XR-ODT methylphenidate TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL 205489-002 Jun 19, 2017 RX Yes No 9,089,496   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
McKesson
Dow
Moodys
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.